Trials / Not Yet Recruiting
Not Yet RecruitingNCT05988177
Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections
Clinical Study on the Efficacy and Safety of Carrimycin Tablets in Hemophagocytic Lymphohistiocytosis Patients With Carbapenem-resistant Infections
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Beijing Friendship Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aimed to investigate the efficacy and safety of Carrimycin tablets in hemophagocytic lymphohistiocytosis patients with Carbapenem-resistant infections.
Detailed description
Hemophagocytic lymphohistiocytosis (HLH) is a critical condition characterized by the undue activation of cytotoxic T lymphocytes, natural killer cells, and macrophages, resulting in excessive secretion of infammatory cytokines. Infection is an important trigger for HLH. This study aimed to investigate the efficacy and safety of Carrimycin tablets in hemophagocytic lymphohistiocytosis patients with Carbapenem-resistant infections.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Carrimycin tablets | Carrimycin tablets are administered 400mg a day orally for 7 days. |
Timeline
- Start date
- 2023-08-30
- Primary completion
- 2026-08-30
- Completion
- 2026-12-30
- First posted
- 2023-08-14
- Last updated
- 2023-08-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05988177. Inclusion in this directory is not an endorsement.